Related Experiment Video
Updated: May 22, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
mTORC 2:1 for chemotherapy sensitization in glioblastoma
Wolfgang Wick1, Jonas Blaes, Markus Weiler
1Clinical Cooperation Unit Neurooncology, German Cancer Research Center, Department of Neurooncology at the National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany. wolfgang.wick@med.uni-heidelberg.de
Abstract:
mTOR signaling is frequently deregulated in cancer, including brain tumors. Although the signaling of mTOR complex 1 (mTORC1) has been subject to intensive investigations and mTORC1 itself has been a well-established cancer drug target for years, the role of the second complex, mTORC2, remains elusive. Tanaka et al. reveal an EGFRvIII-mTORC2-NFκB signaling cascade and demonstrate that mTORC2 mediates cisplatin resistance through NF-κB in an Akt-independent manner in glioblastoma. Uncovering the role of mTORC2 in chemotherapy resistance in glioblastoma highlights the need for further investigations of mTORC2 inhibition.
Insights
This study reveals that the mTORC2 pathway drives cisplatin resistance in glioblastoma by activating NF-κB, independent of Akt. Targeting mTORC2 may overcome chemotherapy resistance in brain tumors.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Deregulation of mTOR signaling is common in cancers, including brain tumors.
- While mTOR complex 1 (mTORC1) is a known drug target, the function of mTOR complex 2 (mTORC2) in cancer remains largely unknown.
- Glioblastoma is an aggressive brain tumor with limited treatment options.
Purpose of the Study:
- To investigate the role of mTORC2 in glioblastoma chemotherapy resistance.
- To elucidate the signaling pathway by which mTORC2 mediates resistance to cisplatin.
- To determine if mTORC2 inhibition could be a therapeutic strategy for glioblastoma.
Main Methods:
- Investigated the EGFRvIII-mTORC2-NFκB signaling cascade in glioblastoma cells.
- Utilized molecular biology techniques to assess the role of mTORC2 and NF-κB in cisplatin resistance.
- Examined the Akt-independent nature of mTORC2-mediated resistance.
Main Results:
- Identified a novel EGFRvIII-mTORC2-NFκB signaling cascade in glioblastoma.
- Demonstrated that mTORC2 mediates cisplatin resistance through NF-κB activation.
- Confirmed that this resistance mechanism is independent of Akt signaling.
Conclusions:
- mTORC2 plays a critical role in mediating chemotherapy resistance in glioblastoma.
- The identified EGFRvIII-mTORC2-NFκB pathway represents a potential therapeutic target.
- Further research into mTORC2 inhibition is warranted for overcoming glioblastoma treatment resistance.
